A Single Arm, 24 Weeks, Pilot Study of Belimumab In Treatment of Early Systemic Lupus Erythematosus
Latest Information Update: 11 Jul 2022
At a glance
- Drugs Belimumab (Primary) ; Azathioprine; Ciclosporin; Cyclophosphamide; Hydroxychloroquine; Leflunomide; Methotrexate; Mycophenolate mofetil; Tacrolimus
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- 05 Jul 2022 Status changed from not yet recruiting to completed.
- 05 Jul 2022 The primary endpoint Response rate of SLEDAI was changed to Lupus low disease activity status (LLDAS), according to ClinicalTrials.gov record.
- 14 Jul 2021 New trial record